Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Acro Biomedical (ACBM) Non-Current Assets (2017 - 2025)

Acro Biomedical (ACBM) has 9 years of Non-Current Assets data on record, last reported at $13651.0 in Q2 2025.

  • For Q2 2025, Non-Current Assets fell 69.22% year-over-year to $13651.0; the TTM value through Dec 2025 reached $33975.0, down 78.75%, while the annual FY2024 figure was $26898.0, 52.67% down from the prior year.
  • Non-Current Assets reached $13651.0 in Q2 2025 per ACBM's latest filing, down from $20324.0 in the prior quarter.
  • Across five years, Non-Current Assets topped out at $56833.0 in Q4 2023 and bottomed at $6268.0 in Q3 2021.
  • Average Non-Current Assets over 5 years is $29931.8, with a median of $28423.5 recorded in 2022.
  • Peak YoY movement for Non-Current Assets: crashed 82.07% in 2021, then soared 481.9% in 2024.
  • A 5-year view of Non-Current Assets shows it stood at $54662.0 in 2021, then tumbled by 45.21% to $29949.0 in 2022, then skyrocketed by 89.77% to $56833.0 in 2023, then tumbled by 52.67% to $26898.0 in 2024, then plummeted by 49.25% to $13651.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Non-Current Assets were $13651.0 in Q2 2025, $20324.0 in Q1 2025, and $26898.0 in Q4 2024.